Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on October 30, 2007
JNCI Journal of the National Cancer Institute 2007 99(21):1645-1646; doi:10.1093/jnci/djm178
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/21/1645    most recent
djm178v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Powles, T. J.
Right arrow Articles by Dowsett, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Powles, T. J.
Right arrow Articles by Dowsett, M.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

CORRESPONDENCE

Responses: Re: Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent Human Epidermal Growth Factor Receptor-Targeted Therapy

Trevor J. Powles, Sue Ashley, Ian E. Smith, Mitch Dowsett

Affiliations of authors: Parkside Oncology Clinic, London, U.K. (TJP); Royal Marsden Hospital, London, U.K. (SA, IES, MD); Institute of Cancer Research, London, U.K. (TJP, IES, MD)

Correspondence to: Trevor J. Powles, PhD, Parkside Oncology Clinic, 49 Parkside, Wimbledon, London SW19 5NB, U.K. (e-mail: hdummer@parkside-hospital.co.uk).

The first 10% of the full text of this article appears below.

The correspondence by Ferretti et al. referring to the paper by Arpino et al. raises important issues related to breast cancer, tamoxifen, and hormone replacement therapy (HRT). The observation in the discussion of Arpino et al. (no data provided) "that the antitumor effect of tamoxifen was lower when estrogen was present than when estrogen was absent" may not be clinically . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer Xenografts With Multiagent Human Epidermal Growth Factor Receptor–Targeted Therapy
Gianluigi Ferretti, Alessandra Felici, and Francesco Cognetti
J Natl Cancer Inst 2007 99: 1644. [Extract] [Full Text] [PDF]